Ayala Pharmaceuticals (NASDAQ:AYLA) Announces Quarterly Earnings Results

Ayala Pharmaceuticals (NASDAQ:AYLA) issued its quarterly earnings data on Monday. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.68), MarketWatch Earnings reports. The business had revenue of $1.00 million during the quarter.

NASDAQ AYLA opened at $11.48 on Thursday. Ayala Pharmaceuticals has a one year low of $10.67 and a one year high of $16.50.

Several equities analysts have weighed in on AYLA shares. Raymond James started coverage on Ayala Pharmaceuticals in a research note on Tuesday, June 9th. They set an “outperform” rating and a $24.00 price objective on the stock. Citigroup assumed coverage on Ayala Pharmaceuticals in a research note on Tuesday, June 2nd. They set a “buy” rating and a $25.00 target price on the stock. Jefferies Financial Group assumed coverage on Ayala Pharmaceuticals in a research note on Tuesday, June 2nd. They set a “hold” rating on the stock. Finally, Oppenheimer assumed coverage on Ayala Pharmaceuticals in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $23.00 target price on the stock.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.

Featured Article: Investing in Dividend Stocks

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.